The program offers multiple perspectives on the HIV cure field, showcasing exciting recent research findings with potential for clinical translation.
The conference sessions will present the latest research and foster discussion on:
• The establishment of the HIV reservoir
• The adaptive and innate immune responses associated with HIV control
• The molecular characteristics of the viral reservoirs
• The development of new therapies
| SUNDAY 22 SEPTEMBER 2024 | |
|---|---|
| OPENING HIV CURE SYMPOSIUM - KEYNOTE LECTURE | |
| 18.00-18.30 | Future directions for HIV Cure research Ole Sogaard, Aarhus University, Denmark |
| 18.30-19.00 | 2000 Project Andre van der Ven, Radboud UMC, The Netherlands |
| 19.00-20.00 | Opening Reception |
| MONDAY 23 SEPTEMBER 2024 | |
|---|---|
| SESSION 1 – ‘VIRAL INTEGRATION’: CHROMOSOMAL ARCHITECTURE | |
| 09.00-09.30 | HIV targeted integration in the context of chromatin structure Monsef Benkirane, Research Director CNRS, France |
| 09.30-10.00 | Integration site selection, genomic features of integration sites and impact of viral expression Angela Ciuffi, CHUV, Switzerland |
| 10.00-10.30 | TBC |
| 10.30-10.50 | Break |
| SESSION 2 – ESTABLISHMENT EVOLUTION AND OR SELECTEION OF THE VIRAL RESERVOIR OVER TIME | |
| 11.00-11.30 | Immune selection of proviral DNA by CTL responses Brad Jones, Weill Cornell Medicine, United States |
| 11.30-12.00 | TBC Linos Vandekerckhove, Ghent University, Belgium |
| 12.00-12.30 | Understanding the viro-immunological mechanisms contributing to HIV control during an analytical treatment interruption Sarah Palmer, The Westmead Institute for Medical Research, Australia |
| 12.30-14.00 | Lunch |
| SESSION 3 – REACTIVATION OF THE VIRAL RESERVOIR | |
| 14.00-14.30 | HIV Expression in Infected T Cell Clones Mary Kearney, National Institute for Medical Research, Australia |
| 14.30-15.00 | Reactivation of the viral reservoir by TAT LNP's Daniel Claiborne, The Wistar Institute, United States |
| 15.00-15.30 | TBCMarion Pardons, Ghent University, Belgium |
| 15.30-15.50 | Break |
| SESSION 4– HOW TO ELIMINATE THE RESERVOIR: LESSONS LEARNED FROM THE CANCER FIELD | |
| 16.00-16.30 | TBC |
| 16.30-17.00 | TBC Rafick Sékaly, Emory University, United States |
| 17.00-17.30 | TBC Sarah Gerlo, Ghent University, Belgium |
| TUESDAY 24 SEPTEMBER 2024 | |
|---|---|
| SESSION 5 – TISSUE: TFH OR TRM? | |
| 09.00-09.30 | CD4+ T cells in HIV: A Friend or a Foe? Costas Petrovas, CHUV, Switzerland |
| 09.30-10.00 | Role of tissue NK cells in HIV persistence Maria Buzon, Vall d’Hebron Institute of Research (VHIR), Spain |
| 10.00-10.30 | Polyfunctional T cell responses in nonhuman primates Susan Pereira, Emory University, Belgium |
| 10.30-10.50 | Break |
| SESSION 6 – INNATE MEMORY | |
| 11.00-11.30 | TBC |
| 11.30-12.00 | TBC |
| 12.00-12.30 | TBC Mihai Netea, Radboud UMC, The Netherlands |
| 12.30-14.00 | Lunch |
| SESSION 7 – MICROBIOME-METABOLOME-PATHOGEN INTERACTIONS | |
| 14.00-14.30 | Interaction metabolome- IL1R1 and HIV reservoir size Quirijn de Mast, Radboud UMC, The Netherlands |
| 14.30-15.00 | TBC |
| 15.00-15.30 | HIV 2000 Consortium Talk TBC |
| 15.30-15.50 | Break |
| SESSION 8– IMMUNE BASED THERAPY TO ELIMINATE THE RESERVOIR | |
| 16.00-16.30 | Assessing immunogenicity barriers of the HIV-1 envelope trimer Rogier Sanders, Amsterdam UMC, The Netherlands |
| 16.30-17.00 | TBC |
| 17.00-17.30 | HIV 2000 Consortium Talk TBC |
| 18.00-20.00 | Poster Session |
| WEDNESDAY 25SEPTEMBER 2024 | |
|---|---|
| SESSION 9 – CELL BASED THERAPY TO ELIMINATE THE RESERVOIR | |
| 09.00-09.30 | Role of immune homeostasis in reaching a low reservoir Ashish Sharma, Emory University, United States |
| 09.30-10.00 | TBC |
| 10.00-10.30 | TBC |
| 10.30-10.50 | Break |
| SESSION 10 – KEY RESULTS FROM HIV 2000 | |
| 11.00-11.30 | HIV 2000 Consortium Talk TBC |
| 11.30-12.00 | HIV 2000 Consortium Talk TBC |
| 12.00-12.30 | HIV 2000 Consortium Talk TBC |